The past several years have been brutal for biotech company Bluebird bio (NASDAQ: BLUE). Shares of the gene-editing specialist are down by 85% since early 2020 as it has had to deal with clinical and regulatory setbacks, not to mention the marketwide headwinds that have impacted all equities.